SYR-472 Open-label Study
Sponsor
Takeda (Industry)
Overall Status
Completed
CT.gov ID
NCT01751360
Collaborator
(none)
14
1
1
4
3.5
Study Details
Study Description
Brief Summary
To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
14 participants
Primary Purpose:
Treatment
Study Start Date
:
Apr 1, 2013
Actual Primary Completion Date
:
Aug 1, 2013
Actual Study Completion Date
:
Aug 1, 2013
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SYR-472 100mg SYR-472 100mg |
Drug: SYR-472
|
Outcome Measures
Primary Outcome Measures
- Blood Glucose [7 days]
Blood Glucose
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
- The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.
Exclusion Criteria:
-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease
. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Suita-shi | Osaka | Japan |
Sponsors and Collaborators
- Takeda
Investigators
- Study Director: General Manager, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Takeda
ClinicalTrials.gov Identifier:
NCT01751360
Other Study ID Numbers:
- SYR-472/OCT-002
- U1111-1137-2768
- JapicCTI-122024
First Posted:
Dec 18, 2012
Last Update Posted:
Nov 7, 2013
Last Verified:
Nov 1, 2013